Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386367098> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4386367098 endingPage "33" @default.
- W4386367098 startingPage "21" @default.
- W4386367098 abstract "Objective — to optimize of early diagnosis of fibrosis in patients with NAFLD with obesity and overweight based on ROC analysis of non‑invasive laboratory and instrumental diagnostic markers. Materials and methods. The study included 120 patients with NAFLD (main group) with 1 — 3 degrees of obesity or overweight (BMI ≥25.0 — 39.9 kg/m2) and 20 practically healthy volunteers (control group) 23.50 [21.35; 24.78] kg/m2. Patients in the main group were divided into two subgroups depending on BMI. The subgroup I included 85 patients with NAFLD with concomitant obesity, BMI 36.50 [32.00; 40.60] kg/m2, and the subgroup II included 35 patients with NAFLD and overweight 28.00 [27.10; 29.35] kg/m2. Determination of the degree of fibrosis according to the METAVIR scale by measuring the average stiffness of the liver parenchyma, in the mode of shear wave elastography (ultrasound scanning system Soneus P7). The composition of the gut microbiota at the level of the main phylotypes was studied by identifying total bacterial DNA and DNA of Bacteroidetes, Firmicutes, as well as their ratio (F/B ratio), by quantitative real‑time polymerase chain reaction using universal primers for the 16S rRNA gene and taxon‑specific primers. Statistical processing was performed using Statistica 13.1. The data are presented in the form of Me [LQ; UQ], where Me is the median, LQ and UQ are the lower and upper quartiles, respectively. Results. Determination of the characteristic curves obtained as a result of the analysis allowed us to identify the most informationally significant additional diagnostic indicators: CRP, TNF‑α, microRNA‑122, microRNA‑34a (RU), the percentage of visceral fat, and F/B ratio. The analysis of ROC curves allowed us to determine the cut‑off value for each of the additional diagnostic criteria: cut‑off value for serum CRP concentration — 4.5 mg/l (AUC=0.99, sensitivity 1.00, specificity 0.030; p <0.05); for the serum concentration of TNF‑α — 5.5 pg/mL (AUC=0.97, sensitivity 0.98, specificity 0.025; p <0.05). The cut‑off value for the serum level of microRNA‑122 — 12.50 RU (AUC=0.99, sensitivity 0.98, specificity 0.048; p <0.05); for the serum level of microRNA‑34a — 5.50 RU (AUC=0.98, sensitivity 0.98, specificity 0.106; p <0.05). The cut‑off value for the proportion of VF — 8.5% (AUC=0.99, sensitivity 1.00, specificity 0.175; p <0.05); for F/B ratio — 1.51 (AUC=0.95, sensitivity 0.83, specificity 0.021; p <0.05). The analysis of the studied parameters allowed us to develop an algorithm for early comprehensive diagnosis of fibrosis in patients with NAFLD with obesity and overweight. The algorithm we propose consists of the following 4 stages. Stage I includes assessment of hepatopathy and interviewing the patient to determine complaints and anamnesis to exclude etiologic factors of secondary fatty liver. Stage II includes the determination of cytolysis markers, namely ALT and GGT. Stage III includes the determination of metabolic and proinflammatory parameters: HOMA index; TC and LDL cholesterol; CRP and TNF‑α. Stage IV includes the assessment of genetic and biological factors: determination of the main phylotypes of the gut microbiota and measurement of serum concentrations of microRNA‑122 and microRNA‑34a. The algorithm allows screening patients with NAFLD with obesity and overweight and identifying patients with early stages of fibrosis through a phased examination. Conclusions. The generalization of traditional diagnostic algorithms with the results of our search for additional diagnostic criteria made it possible to create a 4‑stage algorithm for early comprehensive diagnosis of fibrosis in patients with NAFLD with concomitant obesity or overweight. The use of the developed algorithm allows stratifying patients with NAFLD with obesity and overweight by the presence of fibrosis in the early stages, including by level of care, and timely prescribing preventive and therapeutic measures to reduce the risk of development, improve prognosis and prevent progression." @default.
- W4386367098 created "2023-09-02" @default.
- W4386367098 creator A5001042234 @default.
- W4386367098 creator A5013313586 @default.
- W4386367098 date "2023-08-31" @default.
- W4386367098 modified "2023-09-28" @default.
- W4386367098 title "Optimization of early diagnosis of fibrosis in patients with non-alcoholic fatty liver disease with obesity and overweight" @default.
- W4386367098 doi "https://doi.org/10.30978/mg-2023-4-21" @default.
- W4386367098 hasPublicationYear "2023" @default.
- W4386367098 type Work @default.
- W4386367098 citedByCount "0" @default.
- W4386367098 crossrefType "journal-article" @default.
- W4386367098 hasAuthorship W4386367098A5001042234 @default.
- W4386367098 hasAuthorship W4386367098A5013313586 @default.
- W4386367098 hasBestOaLocation W43863670981 @default.
- W4386367098 hasConcept C126322002 @default.
- W4386367098 hasConcept C2776954865 @default.
- W4386367098 hasConcept C2778772119 @default.
- W4386367098 hasConcept C2779134260 @default.
- W4386367098 hasConcept C2780559512 @default.
- W4386367098 hasConcept C2780586474 @default.
- W4386367098 hasConcept C2780826214 @default.
- W4386367098 hasConcept C2994217296 @default.
- W4386367098 hasConcept C511355011 @default.
- W4386367098 hasConcept C71924100 @default.
- W4386367098 hasConcept C90924648 @default.
- W4386367098 hasConceptScore W4386367098C126322002 @default.
- W4386367098 hasConceptScore W4386367098C2776954865 @default.
- W4386367098 hasConceptScore W4386367098C2778772119 @default.
- W4386367098 hasConceptScore W4386367098C2779134260 @default.
- W4386367098 hasConceptScore W4386367098C2780559512 @default.
- W4386367098 hasConceptScore W4386367098C2780586474 @default.
- W4386367098 hasConceptScore W4386367098C2780826214 @default.
- W4386367098 hasConceptScore W4386367098C2994217296 @default.
- W4386367098 hasConceptScore W4386367098C511355011 @default.
- W4386367098 hasConceptScore W4386367098C71924100 @default.
- W4386367098 hasConceptScore W4386367098C90924648 @default.
- W4386367098 hasIssue "4" @default.
- W4386367098 hasLocation W43863670981 @default.
- W4386367098 hasOpenAccess W4386367098 @default.
- W4386367098 hasPrimaryLocation W43863670981 @default.
- W4386367098 hasRelatedWork W2001056503 @default.
- W4386367098 hasRelatedWork W2024399215 @default.
- W4386367098 hasRelatedWork W2325047430 @default.
- W4386367098 hasRelatedWork W2333604368 @default.
- W4386367098 hasRelatedWork W2363069330 @default.
- W4386367098 hasRelatedWork W2398103966 @default.
- W4386367098 hasRelatedWork W2509438375 @default.
- W4386367098 hasRelatedWork W4280648188 @default.
- W4386367098 hasRelatedWork W4295082376 @default.
- W4386367098 hasRelatedWork W4313487991 @default.
- W4386367098 isParatext "false" @default.
- W4386367098 isRetracted "false" @default.
- W4386367098 workType "article" @default.